ZymeTx: flu management program could be catching

Published By Datamonitor

Zurich: unthreading its needle

The sale of Threadneedle is the Zurich's latest effort to balance its books following heavy losses on its equity portfolio. Zurich has already announced heavy cost-cuts and has completed a rights issue to increase funds. With strong branding and performance Threadneedle is an attractive target, but finding a buyer might be tricky in the current market.

Published By Datamonitor

Zurich: joining the list of insurance gloom

Zurich's fall into the red was driven by the September 11 tragedy combined with a general economic slowdown. Simultaneously, the insurer's payouts rocketed while its investment income plummeted. On the positive side, 2001 was a difficult year for many insurers throughout the world. Things should get better this year.

Published By Datamonitor

Zurich Financial: taking desperate measures

Once seen as one of the world's strongest companies, Zurich Financial has been forced into a desperate share issue and job cuts by mistaken acquisitions and poor risk assessment. Although its short-term future looks volatile, there's strong growth set for insurance market that will help Zurich and its competitors in the long term.

Published By Datamonitor

Zurich Financial Services: aiming to net the wealthy

Zurich has launched its high net worth division, Zurich Private Client. The HNW market has stimulated a lot of interest recently, and Zurich hopes the insurance venture will help it move into further HNW services in the future. Its already large over-60 and high-income customer base suggests Zurich has a high potential for success in this market.

Published By Datamonitor

Zimmer: spinal expansion would maximize Collagraft potential

The recent approval for these indications allows Zimmer to compete in the largest segment of the $200 million US market for bone growth substitutes. However, unless the company fully enters the spinal implant market - including the establishment of a spinal salesforce - Collagraft will not reach its sales potential.

Published By Datamonitor

Zimmer: big advances through tiny holes

Zimmer has released positive preliminary results for its two-incision minimally invasive hip arthroplasty system, and also plans to open a training facility teaching surgeons how to implant these systems. But while the system can radically reduce recovery time, it involves an extremely difficult technique that most orthopaedic surgeons are unlikely to adopt.

Published By Datamonitor

Yukos: taking control of a crucial oil export route

Yukos, Russia's second largest oil company, will pay $74 million for 49% of the export pipeline operator. The deal will allow Yukos to export more oil to western Europe, boosting its position in Europe's oil market and helping it come out of the shade of its larger rival Lukoil.

Published By Datamonitor

Yukos: Russia set to invade Europe

While there are many bidders for BP's surplus German oil businesses, Yukos is one of the frontrunners to purchase the 650 service stations and 45% share in a refinery. Yukos has earmarked $2 billion towards improving its position in western European refining and retailing. Alongside fellow Russian firm Lukoil, Yukos is definitely a company to watch.

Published By Datamonitor

Youth spending power: rising by 5% per year

Published By Datamonitor